RWA Wealth Partners LLC Decreases Stock Position in Quanterix Co. (NASDAQ:QTRX)

RWA Wealth Partners LLC reduced its holdings in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,602 shares of the company's stock after selling 96,601 shares during the period. RWA Wealth Partners LLC owned 0.25% of Quanterix worth $1,027,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Portolan Capital Management LLC grew its stake in shares of Quanterix by 31.4% in the 3rd quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company's stock valued at $32,668,000 after buying an additional 602,656 shares during the period. Vanguard Group Inc. grew its stake in Quanterix by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company's stock valued at $23,569,000 after acquiring an additional 19,386 shares during the period. William Blair Investment Management LLC bought a new stake in shares of Quanterix during the fourth quarter valued at approximately $11,290,000. Easterly Investment Partners LLC raised its position in shares of Quanterix by 9.0% during the fourth quarter. Easterly Investment Partners LLC now owns 954,995 shares of the company's stock worth $10,152,000 after purchasing an additional 78,862 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Quanterix by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 858,667 shares of the company's stock worth $11,131,000 after purchasing an additional 18,231 shares in the last quarter. 86.48% of the stock is owned by institutional investors.

Quanterix Price Performance

Shares of QTRX stock traded down $0.27 on Friday, hitting $5.94. The stock had a trading volume of 986,288 shares, compared to its average volume of 520,527. Quanterix Co. has a 12-month low of $5.62 and a 12-month high of $21.89. The stock has a market cap of $230.33 million, a price-to-earnings ratio of -5.60 and a beta of 1.35. The business has a 50 day moving average of $7.66 and a 200 day moving average of $10.42.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The business had revenue of $35.16 million for the quarter, compared to analysts' expectations of $34.93 million. As a group, research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

QTRX has been the topic of a number of recent research reports. Canaccord Genuity Group dropped their price objective on shares of Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.